Publications by authors named "Marta Mas-Romero"
Objectives: To determine whether the interaction between frailty status and depression risk is associated with hospitalization density in older adults.
Methods: Ongoing cohort study in 794 subjects aged over 70 years from Albacete (Spain). Data were collected on depression risk, frailty, hospitalizations, and covariates.
Objective: To analyze the psychological and functional sequelae of the COVID-19 pandemic among older adults living in long term care facilities (LTCFs).
Design: Cohort longitudinal study SETTING ANT PARTICIPANTS: A total of 215 residents ≥ 65 years without moderate-to-severe cognitive impairment, living in five LTCFs in Albacete (Spain).
Measurements: Baseline on-site data were collected between March - June 2020 and three-month follow-up between June to September 2020.
Background: There is incomplete information regarding evolution of antibody titers against SARS-CoV-2 after a two-dose strategy vaccination with BNT162b2 in older adults in long-term care facilities (LTCFs) with frailty, disability, or cognitive impairment. We aimed to determine IgG antibody titer loss in older adults in LTCFs.
Methods: This is a multicenter longitudinal cohort study including 127 residents (90 females and 37 males) with a mean age of 82.
Frailty predisposes older persons to adverse events, and information and communication technologies can play a crucial role to prevent them. CAPACITY provides a means to remotely monitor variables with high predictive power for adverse events, enabling preventative personalized early interventions. This study aims at evaluating the usability, user experience, and acceptance of a novel mobile system to prevent disability.
View Article and Find Full Text PDFBackground: Older adults are at the highest risk of severe disease and death due to COVID-19. Randomized data have shown that baricitinib improves outcomes in these patients, but focused stratified analyses of geriatric cohorts are lacking. Our objective was to analyze the efficacy of baricitinib in older adults with COVID-19 moderate-to-severe pneumonia.
View Article and Find Full Text PDFBackground/objectives: The safety and immunogenicity of the BNT162b2 coronavirus disease 2019 (COVID-19) vaccine in older adults with different frailty and disability profiles have not been well determined. Our objective was to analyze immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older adults across frailty and disability profiles.
Design: Multicenter longitudinal cohort study.
Article Synopsis
- AI identified baricitinib as an effective treatment for SARS-CoV-2 pneumonia, showing a 71% mortality benefit in severely ill patients while indicating low adverse effects.
- In elderly patients (median age 81), a majority were able to recover, and additional cases with mild symptoms also showed positive outcomes.
- The drug works by inhibiting certain host proteins, impacting virus entry and replication, and has revealed mechanisms that justify further clinical trials to confirm its effectiveness.
Background/objectives: To analyze mortality, costs, residents and personnel characteristics, in six long-term care facilities (LTCF) during the outbreak of COVID-19 in Spain.
Design: Epidemiological study.
Setting: Six open LTCFs in Albacete (Spain).
Objective: to describe the nutritional status of older adults hospitalized in an acute geriatric unit (AGU) and its association with mortality and days of hospitalization. Material and methods: a retrospective study in 1,084 adults older than 65 years, hospitalized in an AGU. The Mini Nutritional Assessment®-Short Form (MNA®-SF) and subjective global assessment (SGA) were used.
View Article and Find Full Text PDF